UroGen's 16% Jump: Why TD Cowen's $60 Target Has More Room-If ZUSDURI Momentum Holds

TD Cowen's $60 target sits at the high end of consensus

A 15.62% single-session gain usually says more than the chart. For UroGen, the move arrived alongside fresh commercial data that forced analysts to reassess the launch quickly.

The latest input was hard to ignore. ZUSDURI generated $50.4 million in Q2 revenue, up 73% quarter over quarter. When growth compounds this fast, model updates tend to spread beyond a single quarter.

The pricing debate is now about timing, not demand. The Street's 12-month target range is $42 to $60, with an average price target of $47.33. TD Cowen's $60 target sits at the high end of that range. If ZUSDURI momentum continues, the bigger question is whether investors buy before consensus moves again or after part of that move is already reflected in the stock.

URGN is near the top of its 52-week range and above its 200-day simple moving average. That is bullish structure, but it also means expectations are already elevated. With consensus targets still ranging from $42 to $60, the market is effectively deciding whether this launch can keep pushing estimates higher before the move is fully priced in.